<SEC-DOCUMENT>0002027680-25-000002.txt : 20250219
<SEC-HEADER>0002027680-25-000002.hdr.sgml : 20250219
<ACCEPTANCE-DATETIME>20250219075458
ACCESSION NUMBER:		0002027680-25-000002
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250219
DATE AS OF CHANGE:		20250219

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				301341024
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-86699
		FILM NUMBER:		25637205

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Morrison Todd Hale
		CENTRAL INDEX KEY:			0002027680
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		16 APPLETON ST
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0002027680-24-000002</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002027680</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.0001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>02/18/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001505497</issuerCik>
        <issuerName>BioRestorative Therapies, Inc.</issuerName>
        <issuerCusip>090655606</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>40 MARCUS DRIVE</com:street1>
          <com:street2>40 MARCUS DRIVE</com:street2>
          <com:city>MELVILLE</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>11747</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Morrison Todd Hale</reportingPersonName>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>BioRestorative Therapies, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>40 MARCUS DRIVE, 40 MARCUS DRIVE, MELVILLE, NEW YORK, 11747.</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Todd Hale Morrison</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>residence</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States of America</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of the close of business on February 18, 2025, the Reporting Person owned 630,000 shares of common stock</amountBeneficiallyOwned>
        <classPercent>As of the close of business on February 18, 2025, the Reporting Person beneficially owned approximately 9.1% of the outstanding shares of the Issuer's Common Stock, which percentage was calculated based on 6,919,919 shares of the Issuer's Common Stock outstanding as of November 12, 2024, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024 </classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>630000 </sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>630000 </sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.

</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Morrison Todd Hale</reportingPersonName>
      <signatureDetails>
        <signature>Todd Hale Morrison</signature>
        <title>individual</title>
        <date>02/19/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
